ArticleBrain and behavior2022
Ginsenoside Rh2 administration produces crucial antidepressant-like effects in a CUMS-induced mice model of depression.
Article in Brain and behavior, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.
- Systematic review and meta-analysis of the antidepressant-like effects of ginsenosides in animal models: comparative behavioral profiles and exploratory dose-stratified analysis.Frontiers in pharmacology · 2026Pooled it
- CREB: A Promising Therapeutic Target for Treating Psychiatric Disorders.Current neuropharmacology · 2024Pooled it
- Traditional Chinese medicine ginseng regulates neurotrophic factors to improve neurodegenerative diseases: A potential strategy for Alzheimer's disease treatment.Journal of ginseng research · 2026Review
- Ginsenosides in the management of depression: a comprehensive pharmacological review.Chinese medicine · 2026Review
- Neuroprotective Effects of C-Phycocyanin in Chronic Unpredictable Mild Stress-Exposed Rats: Regulation of Neuroinflammation and CREB/BDNF Signaling.Neurochemical research · 2026Article
- Natural anti-cancer products: insights from herbal medicine.Chinese medicine · 2025Review
- Article
- Unlocking ginsenosides' therapeutic power with polymer-based delivery systems: current applications and future perspectives.Frontiers in pharmacology · 2025Review
- GluN2A: A Promising Target for Developing Novel Antidepressants.The international journal of neuropsychopharmacology · 2024Review
- Review
- Repetitive transcranial magnetic stimulation ameliorates cognitive deficits in mice with radiation-induced brain injury by attenuating microglial pyroptosis and promoting neurogenesis via BDNF pathway.Cell communication and signaling : CCS · 2024Article
- Ginsenosides: an immunomodulator for the treatment of colorectal cancer.Frontiers in pharmacology · 2024Review
- Exploring the mechanism of Icariin in the treatment of depression through BDNF-TrkB pathway based on network pharmacology.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Role of BDNF-TrkB signaling in the antidepressant-like actions of loganin, the main active compound of Corni Fructus.CNS neuroscience & therapeutics · 2023Article
- Evaluation of the Anti-Inflammatory Pain Effect of Ginsenoside-Conjugated O-Carboxymethyl Chitosan Particles.Polymers · 2023Article
- Adult hippocampal neurogenesis: pharmacological mechanisms of antidepressant active ingredients in traditional Chinese medicine.Frontiers in pharmacology · 2023Review
- Ginsenoside Rh2 administration produces crucial antidepressant-like effects in a CUMS-induced mice model of depression.Brain and behavior · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe most striking feature of depression is sadness and a loss of interest in activities, which represents a major cause of disability globally. Therefore, it is necessary to identify novel antidepressants for clinical practice. Ginsenoside Rh2 (Rh2) is one of the major bioactive ginsenosides that can be extracted from Panax ginseng and has been demonstrated to improve both memory and learning. The purpose of this study was to provide broad insight into the mechanisms underlying depression and gain greater insights into antidepressant therapy.
methodsIn this study, we first established an effective and feasible depression animal model of chronic unpredictable mild stress (CUMS) and behavioral testing was evaluated by the forced swim test (FST), the tail suspension test (TST) and the sucrose preference test. Following pretreatment with Rh2 (10 and 20 mg/kg), the immobility time of mice was reduced without affecting locomotor activity in both the FST and TST. Western blotting and immunofluorescence were used to investigate the activation of the hippocampal BDNF signaling pathway and hippocampal neurogenesis.
resultsDifferent concentrations of Rh2 significantly reduced depressive-like symptoms in CUMS-induced mice and downregulated the effects of the BDNF signaling cascade and neurogenesis in the hippocampus. Furthermore, the administration of K252a completely prevented the antidepressant-like activity of Rh2 in mice.
conclusionThe results indicated that Rh2 possesses the antidepression action via the positive regulation of the BDNF-TrkB pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.